BACKGROUND: Recently, we found evidence that intra-nasally administered dopamine (DA), can enter the brain, leading to an immediate increase in extracellular DA levels in striatal subregions. This offers a potential alternative approach to target the brain with exogenous DA, which otherwise cannot cross the blood-brain barrier. Here, we examined whether intra-nasally applied DA also exerts behavioral activity on mesocortical and nigrostriatal dopaminergic functions. METHOD: Male Wistar rats (3-4 months) were tested for potential behavioral effects of intra-nasally applied DA (0.03, 0.3 or 3.0 mg/kg) in the forced swimming test (FST) for antidepressant-like activity, elevated plus-maze for anxiety-related behavior, and on motor activity in a novel and familiar environment. RESULTS: Intra-nasally administered dopamine in a dose of 0.3 mg/kg exerted antidepressant-like activity in the FST, but had neither anxiolytic-like nor anxiogenic-like effects in the elevated plus-maze. Furthermore, intra-nasal dopamine stimulated locomotor activity in a familiar, but not novel, open field. CONCLUSIONS: These results support the view that intra-nasally applied DA can act on the central nervous system by entering the brain via the nose-brain pathway, making this kind of application procedure a promising alternative for targeting the brain, and thus treating disorders involving mesocortical and/or nigrostriatal dopaminergic disturbances. 2008 S. Karger AG, Basel.
BACKGROUND: Recently, we found evidence that intra-nasally administered dopamine (DA), can enter the brain, leading to an immediate increase in extracellular DA levels in striatal subregions. This offers a potential alternative approach to target the brain with exogenous DA, which otherwise cannot cross the blood-brain barrier. Here, we examined whether intra-nasally applied DA also exerts behavioral activity on mesocortical and nigrostriatal dopaminergic functions. METHOD: Male Wistar rats (3-4 months) were tested for potential behavioral effects of intra-nasally applied DA (0.03, 0.3 or 3.0 mg/kg) in the forced swimming test (FST) for antidepressant-like activity, elevated plus-maze for anxiety-related behavior, and on motor activity in a novel and familiar environment. RESULTS: Intra-nasally administered dopamine in a dose of 0.3 mg/kg exerted antidepressant-like activity in the FST, but had neither anxiolytic-like nor anxiogenic-like effects in the elevated plus-maze. Furthermore, intra-nasal dopamine stimulated locomotor activity in a familiar, but not novel, open field. CONCLUSIONS: These results support the view that intra-nasally applied DA can act on the central nervous system by entering the brain via the nose-brain pathway, making this kind of application procedure a promising alternative for targeting the brain, and thus treating disorders involving mesocortical and/or nigrostriatal dopaminergic disturbances. 2008 S. Karger AG, Basel.
Authors: Dalin Li; Stephanie J London; Jinghua Liu; Wonho Lee; Xuejuan Jiang; David Van Den Berg; Andrew W Bergen; Denise Nishita; Nahid Waleh; Gary E Swan; Peggy Gallaher; Chih-Ping Chou; Jean C Shih; Jennifer B Unger; W James Gauderman; Frank Gilliland; C Anderson Johnson; David V Conti Journal: Am J Epidemiol Date: 2011-03-16 Impact factor: 4.897
Authors: J Daniel Obray; Christina A Small; Emily K Baldwin; Eun Young Jang; Jin Gyeom Lee; Chae Ha Yang; Jordan T Yorgason; Scott C Steffensen Journal: Front Cell Neurosci Date: 2022-07-12 Impact factor: 6.147
Authors: Maria A de Souza Silva; Claudia Mattern; Cvetana Decheva; Joseph P Huston; Adolfo G Sadile; Markus Beu; H-W Müller; Susanne Nikolaus Journal: Front Behav Neurosci Date: 2016-04-22 Impact factor: 3.558